Supplementary Figures 1-9 from Recombinant MDA-7/IL24 Suppresses Prostate Cancer Bone Metastasis through Downregulation of the Akt/Mcl-1 Pathway

Supplementary Figure 1: Preliminary study defined optimum dose of MDA-7/IL-24 and the number of injections to achieve a maximum effect with or without BI-97D6 (1.5 mg/kg). Supplementary Figure 2: Effect of MDA-7/IL-24 on normal primary mouse bone marrow cells. Supplementary Figure 3: Effect of His-MDA-7 on osteoclast differentiation. Supplementary Figure 4: Effect of MDA-7/IL-24 on the osteoclastic gene regulation pattern and growth of RAW 264.7 and DU-145 cells. Supplementary Figure 5: Quantification of the Western Blots shown in figure 3 using image J software (n=3). Supplementary Figure 6: Effect of Mcl-1 inhibitors on osteoclast differentiation and effect of MDA-7/IL-24 on the osteoclast differentiation process. Supplementary Figure 7: Effect of Akt and Mcl-1 expression on osteoclast differentiation. Supplementary Figure 8: Western blots showing the downstream signaling cascades in Akt overexpressing stable PC3-ML cells. Clone 1 showed significant up regulation in p-Akt, p-GSK3β, and cyclin-D1 expression. Supplementary Figure 9: Mice received intra-cardiac injection of PC3-ML luc cells (1 X105) and were treated with recombinant MDA-7 protein (5mg/kg) for 6 doses as described in materials and methods. Mice were imaged by IVIS imaging system.